An anonymous reader shares a report: OpenAI is preparing to launch a frontal assault on Google. The ChatGPT owner recently considered developing a web browser that it would combine with its chatbot, and it has separately discussed or struck deals to power search features for travel, food, real estate and retail websites, according to people who have seen prototypes or designs of the products.

OpenAI has spoken about the search product with website and app developers such as Conde Nast, Redfin, Eventbrite and Priceline, these people said. OpenAI also has discussed powering artificial intelligence features on devices made by Samsung, a key Google business partner, similar to a deal OpenAI recently struck with Apple, according to people who were briefed about the situation at OpenAI.

According to Canalys Research, Microsoft's plan to end support for Windows 10 could result in about 240 million computers being sent to landfills. "The electronic waste from these PCs could weigh an estimated 480 million kilograms, equivalent to 320,000 cars," adds Reuters. From the report: While many PCs could remain functional for years post the end of OS support, Canalys warned demand for devices without security updates could be low. Microsoft announced a plan to provide security updates for Windows 10 devices until October 2028 for an undisclosed annual price. If the pricing structure for extended Windows 10 support mirrors past trends, migrating to newer PCs could be more cost-effective, increasing the number of older PCs heading to scrap, Canalys said.

In 2005, the reclassification of pseudoephedrine to behind-the-counter status led to widespread use of oral phenylephrine in OTC decongestants, despite evidence of its ineffectiveness. Randy Hatton, a clinical professor in the College of Pharmacy at the University of Florida, and his colleague worked to bring this issue to the FDA's attention, revealing loopholes in the regulatory process for older OTC drugs. Hatton writes in an opinion piece for Scientific American: Before the FDA required that drugs had to be proven effective, it determined whether OTC drugs were effective through expert panels that reviewed existing data. These OTC monographs establish what older OTC ingredients can be marketed without FDA approval. The oral decongestant monograph panel reviewed a few published studies and multiple unpublished studies for phenylephrine. Of the unpublished studies, only four studies showed oral phenylephrine was effective, while seven showed it was no better than placebo. We requested copies of all evidence used by the nasal decongestant review panel via a Freedom of Information Act request and performed a systematic review and meta-analysis ourselves. [...]

The FDA has multiple regulatory processes for different types of medicinal compounds. People are perhaps most familiar with the New Drug Application process, which leads to clinical trials for prescription drug approvals. However, many OTC or nonprescription drugs are regulated differently. In fact, a law passed in 1951, the Durham-Humphrey Amendment to the 1938 Food, Drug, and Cosmetic Act, created the categories of prescription and nonprescription drugs. In 1962, the act was amended again so that drugs had to be shown to be effective, hence the requirement for well-done clinical trials. But what about the drugs that were approved before 1962? This is the loophole that some OTC drugs fall through. For prescription drugs, FDA tried to address pre-1962 approvals through a review of over 3,000 prescription drugs. Most of those drugs have now been reviewed and addressed, but there are still unapproved prescription drugs on the market today, such as an extended-release form of oral nitroglycerin. For nonprescription drugs, FDA established the OTC monograph process 10 years after the 1962 amendment to the Food, Drug, and Cosmetic Act, which required products not proven effective to be reconsidered. FDA formed advisory panels grouping hundreds of ingredients into 26 categories based on the products' uses. After gathering all available information, both published and unpublished, from manufacturers, the advisory panels issued final reports to FDA about whether these ingredients were GRASE (generally recognized as safe and effective), not GRASE, or inconclusive. GRASE ingredients can be used in nonprescription drugs without FDA approval if the use matches the monograph. "The oral phenylephrine example shows that FDA needs more funding to look at these old drugs," concludes Hatton. "We need public funds to support independent researchers who want to examine these products objectively. The government should be able to spend millions to save consumers billions on ineffective products. Companies that market these products have no incentive to prove they don't work. Nonprescription drugs must be effective -- not just safe."

During a meeting of the National Space Council, Vice President Kamala Harris said an international astronaut will land on the Moon during one of NASA's Artemis missions. "Today, in recognition of the essential role that our allies and partners play in the Artemis program, I am proud to announce that alongside American astronauts, we intend to land an international astronaut on the surface of the Moon by the end of the decade," Harris said. Ars Technica reports: Although the National Space Council is useful in aggregating disparate interests across the US government to help form more cohesive space policies, public meetings like the one Wednesday can seem perfunctory. Harris departed the stage soon after her speech, and other government officials read from prepared remarks during the rest of the event. Nevertheless, Harris' announcement highlighted the role the space program plays in elevating the soft power of the United States. It was widely assumed an international astronaut would eventually land on the Moon with NASA. Harris put a deadline on achieving this goal.

NASA has long included astronauts from its international partners on human spaceflight missions, dating back to the ninth flight of the space shuttle in 1983, when West German astronaut Ulf Merbold joined five Americans on a flight to low-Earth orbit. This was seen by US government officials as a way to foster closer relations with like-minded countries. The inclusion of foreign astronauts on US missions also repays partner nations who make financial commitments to US-led space projects with a high-profile flight opportunity for one of their citizens.

Among the international partners contributing to Artemis, it seems most likely a European astronaut would get the first slot for a landing with NASA. ESA funded the development of the service modules used on NASA's Orion spacecraft, which will ferry astronauts from Earth to the Moon and back. These modules provide power and propulsion for Orion. ESA is also developing refueling and communications infrastructure for the Gateway mini-space station to be constructed in orbit around the Moon.

A Japanese astronaut might also have a shot at getting a seat on an Artemis landing. Japan's government has committed to providing the life-support system for the Gateway's international habitation module, along with resupply services to deliver cargo to Gateway. Japan is also interested in building a pressurized rover for astronauts to drive across the lunar surface. In recognition of Japan's contributions, NASA last year committed to flying a Japanese astronaut aboard Gateway. Canada is building a robotic arm for Gateway, but a Canadian astronaut already has a seat on NASA's first crewed Artemis mission, albeit without a trip to the lunar surface.

An anonymous reader quotes a report from the Los Angeles Times: It was the late 1980s when Gary Mund felt his pinky tremble. At first it seemed like a random occurrence, but pretty quickly he realized something was seriously wrong. Within two years, Mund -- a crew worker with the Eastern Municipal Water District in Riverside County -- was diagnosed with Parkinson's disease. The illness would eventually consume much of his life, clouding his speech, zapping most of his motor skills and taking away his ability to work and drive. "It sucks," said Mund, 69. He speaks tersely, because every word is a hard-won battle. "I was told the herbicide wouldn't hurt you."

The herbicide is paraquat, an extremely powerful weed killer that Mund sprayed on vegetation as part of his job from about 1980 to 1985. Mund contends the product is responsible for his disease, but the manufacturer denies there is a causal link between the chemical and Parkinson's. Paraquat is manufactured by Syngenta, a Swiss-based company owned by the Chinese government. The chemical is banned in at least 58 countries -- including China and Switzerland -- due to its toxicity, yet it continues to be a popular herbicide in California and other parts of the United States. But research suggests the chemical may cross the blood-brain barrier in a manner that triggers Parkinson's disease, a progressive, neurodegenerative disorder that affects movement. Now, Mund is among thousands of workers suing Syngenta seeking damages and hoping to see the chemical banned.

Since 2017, more than 3,600 lawsuits have been filed in state and federal courts seeking damages from exposure to paraquat products, according to Syngenta's 2022 financial report (PDF). [...] Paraquat is 28 times more toxic than another controversial herbicide, Roundup, according to a report from the Pesticide Action Network. (Roundup has been banned in several parts of California, including a 2019 moratorium by the Los Angeles County Board of Supervisors forbidding its use by county departments.) Paraquat also has other known health effects. It is listed as "highly toxic" on the U.S. Environmental Protection Agency's website, which says that "one small sip can be fatal and there is no antidote." The EPA is currently reviewing paraquat's approval status. However, both the EPA and Syngenta cited a 2020 U.S. government Agricultural Health Study that found there is no clear link between paraquat exposure and Parkinson's disease. A 2021 review of reviews similarly found that there is no causal relationship.

An anonymous reader quotes a report from Electrek: New York City's largest fossil-fuel plant, which powers 20% of the city, will be replaced with offshore wind power. Ravenswood Generating Station is the New York City fossil fuel plant that will become an offshore wind hub. It's a 2,480-megawatt (MW) power plant in Long Island City, Queens, across from Roosevelt Island, and it's the Big Apple's largest power plant. Rise Light & Power, a New York based energy asset manager and developer that holds Ravenswood as its core asset, is submitting a proposal today, with support from community and state leaders, to the New York State Energy Research and Development Authority (NYSERDA) in response to the state's offshore wind solicitation.

In a nutshell, the 27-acre waterfront oil and gas industrial site is going to be converted into a clean energy hub that will power one-fifth of New York City with offshore wind power. The Ravenswood offshore wind project will reuse existing physical and electrical infrastructure, and that's going to save New York ratepayers money. An HVDC conductor cable will be brought onshore at the existing power plant site. The cable will interconnect via underground HVAC cables to the NYISO bulk electric system at existing substations adjacent to the site. It will also become an offshore wind operations and maintenance hub that will support the just transition of the existing fossil fuel plant workforce, and drive economic investment into a historically underserved community. Rise Light & Power states that the project will, with training programs and job opportunities, justly transition and upskill Ravenswood's current Local 1-2 UWUA union workers.

The International Data Corporation has the latest numbers for worldwide smartphone sales in Q4 2022, and it's a disaster. Shipments declined 18.3 percent year-over-year, making for the largest-ever decline in a single quarter and dragging the year down to an 11.3 percent decline. With overall shipments of 1.21 billion phones for the year, the IDC says this is the lowest annual shipment total since 2013. Ars Technica reports: In the top five for Q4 2022 -- in order, they were Apple, Samsung, Xiaomi, Oppo, and Vivo -- Apple was, of course, the least affected, but not by much. Apple saw a year-over-year drop of 14.9 percent for Q4 2022, Samsung was down 15.6 percent, and the big loser, Xiaomi, dropped 26.5 percent. For the year, Samsung still took the No. 1 spot with 21.6 percent market share, Apple was No. 2 with 18.8 percent, and Xiaomi took third place at 12.7 percent.

The IDC also notes consumers are keeping smartphones longer than ever now, with "refresh rates" or the time that passes before people buy a new phone 'climb[ing] past 40 months in most major markets.' The report closes saying: "2023 is set up to be a year of caution as vendors will rethink their portfolio of devices while channels will think twice before taking on excess inventory. However, on a positive note, consumers may find even more generous trade-in offers and promotions continuing well into 2023 as the market will think of new methods to drive upgrades and sell more devices, specifically high-end models."

In his State of the City speech Thursday, New York City Mayor Eric Adams announced that Uber and Lyft will be required to be zero emission by 2030. The decision by one of the world's largest markets for app-based ridehailing has the potential to affect an estimated 100,000 for-hire vehicles. From a report: Adams said the move will build on efforts his administration has made to electrify the city's fleet of vehicles while installing charging infrastructure to power those vehicles throughout the five boroughs. The mayor will likely implement his plan through the city's Taxi and Limousine Commission, which regulates the for-hire vehicle industry, including Uber and Lyft. Uber and Lyft, which normally chafe at new requirements and have been known to sue to block rules they don't like, sound largely positive toward the new development in New York.

Africa is less safe, secure and democratic than a decade ago, with insecurity holding back progress in health, education and economic opportunities, according to an assessment of the continent. From a report: The Ibrahim index of African governance, which examines how well governments have delivered on policies and services, including security, health, education, rights and democratic participation, said Covid had contributed to the stalling of progress over the past three years.

Mo Ibrahim, a Sudan-born businessman who launched the index in 2007, said economic opportunities and human development had improved "quite a lot" across Africa over the past 10 years. "But on the other hand, we see other forces pulling us back. The security and safety of our people is deteriorating," he said. Ibrahim said he was concerned the climate crisis would lead to more conflict over resources, as already seen in parts of Nigeria, Darfur and the Sahel, and worried about the impact of the war in Ukraine on development indicators across the continent.

European Commission: Have you ever struggled to understand whether you were buying directly from Google or from a different brand, or had difficulty finding information about final costs? In order to further align its practices with EU law -- mainly on lack of transparency and clear information to consumers -- Google has committed to introduce changes in several of its products and services. Following a dialogue started in 2021 with the Consumer Protection Cooperation Network (CPC), coordinated by the European Commission and led by the Dutch Authority for Consumers and Markets and the Belgian Directorate-General for Economic Inspection, Google has agreed to address issues raised by the authorities and to introduce changes in Google Store, Google Play Store, Google Hotels and Google Flights to ensure compliance with EU consumer rules.

Following the dialogue, Google has committed to limit its capacity to make unilateral changes related to orders when it comes to price or cancellations, and to create an email address whose use is reserved to consumer protection authorities, so that they can report and request the quick removal of illegal content. Moreover, Google agreed to introduce a series of changes to its practices, such as:

Google Flights and Google Hotels:
1. Make clear to consumers whether they contract directly with Google or whether it is simply acting as an intermediary;
2. Clarify the price used as a reference when discounts are advertised on the platform, as well as the fact that reviews are not verified on Google Hotels;
3. Accept the same transparency commitments as other big accommodation platforms as regards the way it presents information to consumers, for example, on prices or availability.

Google Play Store and Google Store:
1. Provide clear pre-contractual information on delivery costs, right of withdrawal and availability of repair or replacement options. Furthermore, Google will facilitate also information on the company (e.g. legal name and address) and direct and effective contact points (e.g. a live telephone agent);
2. Clarify how to browse different country versions of the Google Play Store and inform developers about their obligations under the Geo-blocking Regulation to make their apps accessible EU-wide, as well as enable consumers to use means of payment from any EU country.

Scientists from the U.S. National Institutes of Health found a link between dozens of different viral exposures and a later increased risk of Alzheimer's disease and other brain disorders. Gizmodo reports: They analyzed data from two existing and nationally representative biobank projects tracking the long-term health of residents in Finland and the UK, respectively, collectively involving around 450,000 people. They looked for links between viral infections that led to hospitalization and six neurodegenerative diseases: Alzheimer's disease (the most common form of dementia), ALS, multiple sclerosis, Parkinson's disease, vascular dementia, and generalized dementia. In the Finland data, they initially identified 45 types of viral exposure potentially linked to a greater risk of neurodegenerative illness. To double-check these results, they then ran the same sort of analysis on the UK data and found a similar relationship for 22 types of viral exposure across both datasets.

Some of these exposures involved specific viral infections, such as influenza, varicella zoster virus (the cause of chickenpox and shingles), and herpes simplex viruses. Others concerned where an infection or its harmful effects took place, such as viral encephalitis or meningitis, types of brain inflammation that can be caused by many different viruses. For some exposures, the risk of subsequent brain illness extended up to 15 years later, while the strongest link was seen between viral encephalitis and Alzheimer's. The team's findings were published earlier this month in Neuron. "As vaccines are currently available for some of the associated viruses, vaccination may be a way to reduce some risk of neurodegenerative disease," the authors note.